Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency
Cinnamon Girl said
Nov 29, 2013
Nov 26th, Ingelheim, Germany - The application for European marketing authorisation of faldaprevir a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency. Boehringer Ingelheim is seeking marketing approval of faldaprevir in combination with pegylated interferon and ribavirin for the treatment of a broad range of patients with genotype-1 hepatitis C, including difficult-to-cure populations such as those with HIV co-infection or advanced liver disease.
Nov 26th, Ingelheim, Germany - The application for European marketing authorisation of faldaprevir a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency. Boehringer Ingelheim is seeking marketing approval of faldaprevir in combination with pegylated interferon and ribavirin for the treatment of a broad range of patients with genotype-1 hepatitis C, including difficult-to-cure populations such as those with HIV co-infection or advanced liver disease.
Full article...
http://hepatitiscnewdrugs.blogspot.co.uk/2013/11/hepatitis-c-boehringer-ingelheims.html